Compare SFNC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SFNC | MLYS |
|---|---|---|
| Founded | 1903 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | N/A | 2023 |
| Metric | SFNC | MLYS |
|---|---|---|
| Price | $19.28 | $37.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.75 | ★ $47.33 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 01-20-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $27.12 | N/A |
| Revenue Next Year | $7.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.00 | $8.24 |
| 52 Week High | $23.44 | $47.65 |
| Indicator | SFNC | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 43.48 |
| Support Level | $19.01 | $36.01 |
| Resistance Level | $19.83 | $39.15 |
| Average True Range (ATR) | 0.41 | 1.81 |
| MACD | 0.04 | -0.16 |
| Stochastic Oscillator | 52.86 | 31.53 |
Simmons First National Corp is a financial holding company. The company through its subsidiaries is engaged in providing banking services including consumer, real estate and commercial loans, checking, savings and time deposits. The company's loan portfolio comprises construction, single-family residential and commercial loans; non-real estate loans, nonaccrual and past due loans; and credit card loans, student loans and other consumer loans. It also offers various products and services such as trust services, investments, agricultural finance lending, equipment lending, insurance, consumer finance and small business administration lending. The business activity of the firm is functioned through the region of the United States.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.